NEW YORK, April 15, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
IntercontinentalExchange, Inc. (NYSE: ICE), The Western Union
Company (NYSE: WU), Essex Property Trust Inc. (NYSE: ESS), Valeant
Pharmaceuticals International, Inc. (NYSE: VRX) and Pharmacyclics
Inc. (NASDAQ: PCYC). Private wealth members receive these notes
ahead of publication. To reserve complementary membership, limited
openings are available at:
http://www.analystsreview.com/1135-100free.
--
IntercontinentalExchange, Inc. Analyst Notes
On April 7, 2014,
IntercontinentalExchange, Inc. (ICE) provided an update on the
first week of trading for Liffe listed 30-Year Ultra Long Gilt
futures, which complements Liffe's existing 10-Year Gilt futures
and seeks to help participants manage their risk exposure to longer
dated UK debt. The contract was launched on March 31, 2014 with strong volumes of 9,214
contracts traded and open interest of 2,634 as on April 4, 2014. Commenting on the development,
David Peniket, President and COO, Liffe and ICE Futures Europe
said, "We would like to thank UK Gilt market participants for
supporting this product launch, which is the first of many new
products. The early participation in the Ultra Long Gilt market
demonstrates the importance of having a full range of maturities to
manage risk in the UK debt markets." The full analyst notes on
IntercontinentalExchange are available to download free of charge
at:
http://www.analystsreview.com/1135-ICE-.pdf
--
The Western Union Company Analyst Notes
On April 9, 2014, The Western Union
Company (Western Union) announced a film partnership deal with 20th
Century Fox for its animated feature RIO 2. According to the
Company, the partnership will expand consumer reach for both the
companies with a joint global marketing campaign including TV
advertising, print, point of sale, online, out-of-home, and social
media. Laston Charriez, Western
Union, SVP (Marketing), US, commented, "RIO 2 provides a new medium
to engage our customers in a fun artistic approach, conveying the
intrinsic connection of one's roots with family and loved ones.
This theme resonates with the sentiments of our customers, and
underscores a brand attribute that Western Union is proud to embody
with its global network of services." The full analyst notes on
Western Union are available to download free of charge at:
http://www.analystsreview.com/1135-WU-.pdf
--
Essex Property Trust Inc. Analyst Notes
On April 8, 2014, Essex Property
Trust, Inc. (Essex Property) announced that its operating
partnership, Essex Portfolio, L.P., has priced a private placement
of $400 million aggregate principal
amount of senior unsecured notes (Notes) at an interest rate of
3.875% per annum. The Notes, maturing on May
1, 2024, were priced at 99.234% of par value with a yield to
maturity of 3.968%. The offering is expected to close on
April 15, 2014 and the interest will
be payable semi-annually with first interest payment due
November 1, 2014. Essex Portfolio
expects to use net proceeds to refinance existing senior unsecured
indebtedness and for general corporate purposes. The Notes have
been assigned a 'BBB+' credit rating with stable outlook by Fitch
Ratings. Essex Property recently became the 18th REIT to join the
S&P 500 index, following the completion of its merger with BRE
Properties in a $4.3 billion deal.
The full analyst notes on Essex Property are available to
download free of charge at:
http://www.analystsreview.com/1135-ESS-.pdf
--
Valeant Pharmaceuticals International, Inc. Analyst
Notes
On March 25, 2014, Valeant
Pharmaceuticals International, Inc. (Valeant) and Actavis Plc
(Actavis) jointly announced that the U.S. Food and Drug
Administration (FDA) has approved the New Drug Application for
Metronidazole 1.3% Vaginal Gel, an antibiotic for the treatment of
bacterial vaginosis (BV). Actavis had acquired the rights to
Metronidazole 1.3% from Valeant in April
2013. Under the terms of the agreement, Actavis will pay
Valeant up to $57 million in up-front
payments, milestone payments and certain guaranteed royalty
payments during the first three years of commercialization
depending on market conditions. Actavis will also pay ongoing
royalties to Valeant after the first three years of
commercialization. Tage Ramakrishna,
M.D. and CMO, Valeant, said, "Valeant is pleased that another
internal R&D compound has been approved by the FDA and will
soon be available." The full analyst notes on Valeant are
available to download free of charge at:
http://www.analystsreview.com/1135-VRX-.pdf
--
Pharmacyclics Inc. Analyst Notes
On April 8, 2014, Pharmacyclics, Inc.
(Pharmacyclics) announced that it has submitted a supplemental New
Drug Application (sNDA) to the U.S. Food and Drug Administration
(FDA), based on data from the randomized, multi-center, open-label
Phase III RESONATETM study, PCYC-1112, a head-to-head comparison of
single agent IMBRUVICATM (ibrutinib) versus ofatumumab in 391
patients with chronic lymphocytic leukemia (CLL) or small
lymphocytic lymphoma (SLL), who had received at least one prior
therapy. According to the Company, IMBRUVICA is being jointly
developed and commercialized by Pharmacyclics and Janssen Biotech,
Inc. Bob Duggan, CEO and Chairman of
the Board, Pharmacyclics, said, "This supplemental new drug
application in previously treated CLL patients is our first Phase
III submission to the FDA seeking full approval for the use of
IMBRUVICA." The full analyst notes on Pharmacyclics
are available to download free of charge at:
http://www.analystsreview.com/1135-PCYC-.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content
to our exclusive membership. We are constantly hiring researchers,
writers, editors and analysts to add to our team and become better
than yesterday. If being a part of a fast growing community with an
edge in today's market sounds interesting to you, then sign-up
today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. This release was produced by first_testproducer
last_testproducer, a CFA charter-holder and reviewed by
Ananya Ghosh, a CFA charter-holder.
If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us
at compliance [at] http://www.analystsreview.com.
6. Would you like to see similar coverage on your company? Send us
a full investors' package to research [at]
http://www.analystsreview.com for consideration.
Please visit http://www.analystsreview.com/disclaimer for our full
legal disclaimer. CFA® and Chartered Financial Analyst® are
registered trademarks owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review